[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012002163A - Agentes novedosos y usos de los mismos. - Google Patents

Agentes novedosos y usos de los mismos.

Info

Publication number
MX2012002163A
MX2012002163A MX2012002163A MX2012002163A MX2012002163A MX 2012002163 A MX2012002163 A MX 2012002163A MX 2012002163 A MX2012002163 A MX 2012002163A MX 2012002163 A MX2012002163 A MX 2012002163A MX 2012002163 A MX2012002163 A MX 2012002163A
Authority
MX
Mexico
Prior art keywords
il1rap
acute
myeloid leukemia
leukemia cells
chronic myeloid
Prior art date
Application number
MX2012002163A
Other languages
English (en)
Other versions
MX336884B (es
Inventor
Thoas Fioretos
Marcus Jaeraas
Original Assignee
Cantargia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantargia Ab filed Critical Cantargia Ab
Publication of MX2012002163A publication Critical patent/MX2012002163A/es
Publication of MX336884B publication Critical patent/MX336884B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01C—MEASURING DISTANCES, LEVELS OR BEARINGS; SURVEYING; NAVIGATION; GYROSCOPIC INSTRUMENTS; PHOTOGRAMMETRY OR VIDEOGRAMMETRY
    • G01C21/00—Navigation; Navigational instruments not provided for in groups G01C1/00 - G01C19/00
    • G01C21/26—Navigation; Navigational instruments not provided for in groups G01C1/00 - G01C19/00 specially adapted for navigation in a road network
    • G01C21/34—Route searching; Route guidance
    • G01C21/36—Input/output arrangements for on-board computers
    • G01C21/3667—Display of a road map
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
    • G06Q50/40—Business processes related to the transportation industry
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/20—Monitoring the location of vehicles belonging to a group, e.g. fleet of vehicles, countable or determined number of vehicles
    • G08G1/202—Dispatching vehicles on the basis of a location, e.g. taxi dispatching
    • G—PHYSICS
    • G08—SIGNALLING
    • G08G—TRAFFIC CONTROL SYSTEMS
    • G08G1/00—Traffic control systems for road vehicles
    • G08G1/20—Monitoring the location of vehicles belonging to a group, e.g. fleet of vehicles, countable or determined number of vehicles
    • G08G1/205—Indicating the location of the monitored vehicles as destination, e.g. accidents, stolen, rental
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H04W4/029—Location-based management or tracking services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
    • H04W8/24—Transfer of terminal data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M2250/00—Details of telephonic subscriber devices
    • H04M2250/10—Details of telephonic subscriber devices including a GPS signal receiver

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Business, Economics & Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Remote Sensing (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Tourism & Hospitality (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invención proporciona agentes que comprenden o consisten de una porción de unión con especificidad para la proteína accesoria del receptor de interleucina 1 (IL1RAP) para uso en la inducción de muerte celular y/o inhibición del crecimiento y/o proliferación de hemocitoblastos patológicos y/o células progenitoras asociadas con un trastorno hematológico neoplásico, en donde las células expresan IL1RAP; un aspecto relacionado de la invención proporciona agentes que comprenden o que consisten de una porción de unión con especificidad para la proteína accesoria del receptor de interleucina 1 (ILIRAP) para uso en la detección de hemocitoblastos patológicos y/o células progenitoras asociadas con un trastorno hematológico neoplásico, en donde las células expresan Ll1RAP; se proporcionan además composiciones farmacéuticas que comprenden los agentes de la invención y los métodos de uso de los mismos.
MX2012002163A 2009-08-21 2010-08-20 Expresión de il 1rap en leucemia. MX336884B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27214609P 2009-08-21 2009-08-21
GB0914644.0A GB2472856B (en) 2009-08-21 2009-08-21 IL1-RAP modulators and uses thereof
US29614310P 2010-01-19 2010-01-19
PCT/GB2010/001612 WO2011021014A2 (en) 2009-08-21 2010-08-20 Novel agents and uses thereof

Publications (2)

Publication Number Publication Date
MX2012002163A true MX2012002163A (es) 2012-07-17
MX336884B MX336884B (es) 2016-02-03

Family

ID=41171735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002163A MX336884B (es) 2009-08-21 2010-08-20 Expresión de il 1rap en leucemia.

Country Status (11)

Country Link
US (3) US9458237B2 (es)
EP (2) EP2985293B1 (es)
JP (1) JP5893559B2 (es)
CN (2) CN107184975A (es)
AU (1) AU2010284846B2 (es)
CA (1) CA2772111C (es)
ES (1) ES2553419T3 (es)
GB (1) GB2472856B (es)
IL (1) IL218108A (es)
MX (1) MX336884B (es)
WO (1) WO2011021014A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271672B1 (en) 2008-03-26 2015-11-11 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
MX354450B (es) 2011-01-19 2018-03-05 Cantargia Ab Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
US20140308294A1 (en) * 2011-04-15 2014-10-16 Merck Patent Gmbh Anti-IL-1R1 Inhibitors For Use in Cancer
WO2013023015A2 (en) 2011-08-11 2013-02-14 Albert Einstein College Of Medicine Of Yeshiva University Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
WO2013096939A1 (en) 2011-12-23 2013-06-27 Sri International Selective binding compounds
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
WO2016085832A1 (en) * 2014-11-24 2016-06-02 Albert Einstein College Of Medicine, Inc. Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
AU2016282869B2 (en) 2015-06-26 2022-08-18 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
WO2017079121A2 (en) 2015-11-02 2017-05-11 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3526247A4 (en) 2016-10-16 2021-04-14 Cantargia AB ANTI-IL1 RAP ANTIBODIES
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharma conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
EP3638697A4 (en) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
SI3642242T1 (sl) * 2017-06-21 2024-05-31 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti
WO2020015805A1 (en) * 2018-07-17 2020-01-23 Eldesouki Raghda Elsawi Badawi A bi-specific antibody to target cd176 and interleukin-1 receptor associated protein on human cancer stem cells.
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
CA3202942A1 (en) 2020-12-23 2022-06-30 David LIBERG Anti-il1rap antibody
CN114736885A (zh) * 2022-05-27 2022-07-12 四川大学华西医院 一种携带bcr-abl1基因激酶区双位点突变的细胞株及其构建方法
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
CN1169754A (zh) * 1995-01-23 1998-01-07 霍夫曼-拉罗奇有限公司 人白介素-1受体辅助蛋白
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
US20030215453A1 (en) 2002-05-14 2003-11-20 Dedera Douglas A. Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7049095B2 (en) * 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
EP1450837A4 (en) * 2001-08-07 2006-01-04 Immunex Corp INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2006214034A1 (en) * 2005-02-16 2006-08-24 Wyeth Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1928506A4 (en) 2005-08-19 2009-10-21 Abbott Lab IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2271672B1 (en) 2008-03-26 2015-11-11 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
GB0823445D0 (en) 2008-12-23 2009-01-28 Univ Surrey Biomarker
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
MX354450B (es) 2011-01-19 2018-03-05 Cantargia Ab Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
AU2016282869B2 (en) 2015-06-26 2022-08-18 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
WO2017079121A2 (en) 2015-11-02 2017-05-11 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
EP3526247A4 (en) 2016-10-16 2021-04-14 Cantargia AB ANTI-IL1 RAP ANTIBODIES
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies

Also Published As

Publication number Publication date
US10878703B2 (en) 2020-12-29
GB0914644D0 (en) 2009-09-30
JP5893559B2 (ja) 2016-03-23
US10005842B2 (en) 2018-06-26
MX336884B (es) 2016-02-03
CN107184975A (zh) 2017-09-22
CA2772111A1 (en) 2011-02-24
ES2553419T3 (es) 2015-12-09
CN102639565B (zh) 2017-05-24
EP2985293B1 (en) 2022-11-30
WO2011021014A2 (en) 2011-02-24
GB2472856A (en) 2011-02-23
IL218108A (en) 2017-09-28
AU2010284846A1 (en) 2012-03-08
IL218108A0 (en) 2012-04-30
CN102639565A (zh) 2012-08-15
WO2011021014A3 (en) 2011-06-16
US20180293895A1 (en) 2018-10-11
US20120225059A1 (en) 2012-09-06
EP2467403A2 (en) 2012-06-27
US20170198048A1 (en) 2017-07-13
CA2772111C (en) 2018-05-01
AU2010284846B2 (en) 2015-10-08
EP2467403B1 (en) 2015-10-21
GB2472856B (en) 2012-07-11
JP2013502403A (ja) 2013-01-24
US9458237B2 (en) 2016-10-04
EP2985293A1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
MX336884B (es) Expresión de il 1rap en leucemia.
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
HK1220899A1 (zh) 鑑於移植用於造血先祖細胞動員的 -苯甲酰基-
UY33647A (es) ?agentes de unión a cd33?.
DE602006020037D1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
MX2009013332A (es) Inhibidores de ire-1 alfa.
WO2009065022A3 (en) Low density lipoprotein receptor-mediated sirna delivery
WO2009077857A3 (en) Trail variants for treating cancer
MX2018006096A (es) Receptores cd27 quimericos para redirigir celulas t a malignidades cd70-positivas.
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
WO2013023015A3 (en) Targets for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes
GB0701223D0 (en) Cable routing clip
SG144146A1 (en) Adenosine receptor agonists
FR2896797B1 (fr) Mousse ceramique en carbure de silicium recristallise impregnee.
WO2012103360A3 (en) Wnt compositions and methods of use thereof
WO2010132389A3 (en) Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
AU321417S (en) Restraint device
AU309832S (en) Note pad for organizer clip
AU320586S (en) Cable clip
AU327040S (en) Filter
MX2007000364A (es) Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.
WO2007124284A3 (en) Bombesin receptor anatogonists with anti-cancer activity
TW200634019A (en) Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
AU327041S (en) Filter
AU327043S (en) Filter

Legal Events

Date Code Title Description
FG Grant or registration